 |
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
2018 News Releases
December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read
December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read
November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results
Read
October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
October 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China
Read
September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read
September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
Read
August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results
Read
July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada
Read
July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
Read
June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Read
May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference
Read
May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results
Read
May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
Read
April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss
First Quarter Financial Results
Read
April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Read
April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases
Read
March 6, 2018 - Puma Biotechnology to Present at Cowen's Annual Healthcare Conference
Read
March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Read
February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read
February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read
February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
Read
January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature -
Read
January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel
Read
January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
